IP Library Granted Patent US 8,449,893
Granted Patent B2
US 8,449,893 · App. 13/141,707 · Granted May 28, 2013

Compositions and dosage regimes comprising a clostridial vaccine and levamisole

Inventor: Wayne Frederick Leech (Auckland, NZ)
Assignee: Bayer New Zealand Limited (17012)
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,449,893
App. No.
13/141,707
Granted
May 28, 2013
Kind
B2
Abstract

A composition and dosage regime including a vaccine and levamisole for the treatment of clostridial diseases and helminthiasis. New methods of administration relating to particular dosage regimes of such a composition are also claimed.

Claims (13)

1. A composition comprising: 10-15% w/v levamisole base and a clostridial vaccine.

2. The composition of claim 1 , wherein the levamisole is present in the form of levamisole phosphate.

3. The composition of claim 2 , wherein the composition includes 22 mg/mL levamisole phosphate.

4. The composition of claim 2 wherein the amount of levamisole phosphate in the composition is 22 w/v%.

5. The composition of claim 1 , wherein the clostridial vaccine is an antigenic preparation for one or more of the diseases selected from the group including gas gangrene, lamb dysentery, struck, pulpy kidney, malignant oedema, blackleg, tetanus, black disease, haemoglobinuria and/or sordelli infections.

6. The composition of claim 5 , wherein the clostridial vaccine includes vaccine for Clostridium perfringens Type D, Clostridium tetani, Clostridium chauvoei, Clostridium septicum and Clostridium novyi Type B.

7. The composition as claimed in claim 1 , wherein the composition includes at least one beneficial substance selected from the group including cobalamins, cyanocobalamins and selenium.

8. The composition of claim 7 , wherein the beneficial substance is vitamin B12, at a concentration of 0.5-1.4 mg/ml.

9. The composition as claimed in claim 1 , wherein the composition is injectable.

10. A method of treating animals for one or more of the diseases selected from the group including gas gangrene, lamb dysentery, struck, pulpy kidney, malignant oedema, blackleg, tetanus, black disease, haemoglobinuria and/or sordelli infections, comprising the step of administering to the animal a composition comprising: 10-15% w/v levamisole base and a clostridial vaccine.

11. The method of claim 10 , wherein the animal to be treated is a ruminant.

12. The method of claim 10 , wherein the composition is administered to an animal in need thereof according to the following dosage regime: in the amount of 1.8-2.2 ml per 36-45 kg of animal weight, 2.3-2.7 mL per 46-55 kg of animal weight, 2.8-3.2 mL per 56-65 kg of animal weight, 3.3-3.7 mL per 66-75 kg of animal weight, 3.8-4.2 mL per 76-85 kg of animal weight, 4.3-4.7 mL per 86-95 kg of animal weight, 4.8-5.2 mL per 96-105 kg animal weight, 4.8-5.2 mL per 96-105 kg animal weight, and 5.3-5.9 mL per 106 kg of animal weight.

13. The method of claim 10 , wherein the composition is administered to the animal according to the following dosage regime: in the amount 2.0 ml per 36-45 kg of animal weight, 2.5 mL per 46-55 kg of animal weight, 3.0 mL per 56-65 kg of animal weight, 3.5 mL per 66-75 kg of animal weight, 4.0 mL per 76-85 kg of animal weight, and 0.5 mL per 10kg of bodyweight for animals over 85 kg.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 9, 2020
From: BAYER NEW ZEALAND LTD.
To: ELANCO NEW ZEALAND
Reel/Frame 054017/0624 →
MERGER Recorded Feb 27, 2013
From: BOMAC INDUSTRIES LIMITED (66249); BOMAC LABORATORIES LIMITED (261510); BOMAC RESEARCH LIMITED (986752); MASTITIS RESEARCH CENTRE LIMITED (1698553); BAYER NEW ZEALAND LIMITED (17012)
To: BAYER NEW ZEALAND LIMITED (17012)
Reel/Frame 029891/0464 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2011
From: LEECH, WAYNE FREDERICK
To: BOMAC RESEARCH LIMITED
Reel/Frame 026859/0102 →
Priority Claims (1)
NZ 574018 · Dec 24, 2008 · national
Continuity (1)
Related Publication 20110311589A1 · Dec 22, 2011